As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...
ROOTSTOWN, Ohio, August 07, 2025--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with epidermolysis bullosa simplex treated with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Diacerein 1% did not outperform vehicle in study ...
ROOTSTOWN, Ohio, Oct. 30, 2023 /PRNewswire/ -- BioMendics LLC, a pharmaceutical company developing new medicines to improve the lives of patients living with rare skin diseases, today announced its ...
The patient has the Hallopeau-Siemens variant of dystrophic epidermolysis bullosa (EB). EB comprises a group of rare genetic states that are characterized by extremely fragile skin and recurrent ...
Dermatology Nursing. 2005;17(1):56-59. The "Clinical Snapshot" series provides a concise examination of a clinical presentation including history, treatment, patient education, and nursing measures.
ROOTSTOWN, Ohio, January 06, 2026--(BUSINESS WIRE)--As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results